Schizophrenia study: Buprenorphine
Official title Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
ClinicalTrials.gov ID: NCT05778591
What this study is testing
What is Buprenorphine 0.15 MG [Belbuca]?
Buprenorphine 0.15 MG [Belbuca] is an investigational medicine, being studied as a potential treatment for schizophrenia.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if a small dose of buprenorphine can increase the desire to engage socially and reduce avoidance of social situations in people with schizophrenia.
- Who it's for
- Adults diagnosed with schizophrenia who meet the study’s eligibility criteria.
- What's involved
- Participants will attend a 2‑hour orientation and two 6‑hour lab visits where they receive either buprenorphine (0.15 mg) or a placebo, then complete tasks that measure social motivation.
- Time commitment
- The trial lasts for the three visits over a short period, each lasting several hours.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Ages 18-60
- able to understand spoken English sufficiently to comprehend testing procedures
- score below the mean of participants screened previously screened on the Lubben Social Network Scale
- DSM-5 diagnosis of schizophrenia
- clinical stability (i.e., no inpatient hospitalizations for six months prior to enrollment, no changes in medication in for 6 months prior to...
See the full eligibility criteria
- Ages 18-60
- able to understand spoken English sufficiently to comprehend testing procedures
- score below the mean of participants screened previously screened on the Lubben Social Network Scale
- DSM-5 diagnosis of schizophrenia
- clinical stability (i.e., no inpatient hospitalizations for six months prior to enrollment, no changes in medication in for 6 months prior to enrollment, no current positive symptoms greater than moderate) c) no history...
- no history of serious head injury (i.e., loss of consciousness longer than 1 hour, neuropsychological sequelae, cognitive rehabilitation treatment after head injury) based on medical history
- no substance or alcohol use disorder in the past six months, or history of opioid use disorder
- no sedatives, benzodiazepines within 24 hours of testing
- no positive urine toxicology screen or visible intoxication on the day of assessment
- no women who are pregnant or think that they might be pregnant, based on self-report and urine test
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.